uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.540 | Q34 | What are the names of the genes that are targeted by the drug Azelastine Hydrochloride in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Azelastine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%azelastine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%azelastine hydrochloride%" OR LOWER(syns_list) LIKE "%azelastine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455908', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455868', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455940', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455883', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455867', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455914', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455891', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455876', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455932', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455899', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455939', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455875', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455907', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455931', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455916', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455915', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455874', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455946', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455890', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455922', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455923', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455892', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455930', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455938', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455900', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455947', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455924', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455906', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455898', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455884', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455948', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455882', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455866', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455864', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455880', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455896', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455928', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455872', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455936', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455904', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455944', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455888', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455912', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455920', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.817 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of gout? | In the context of gout, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gout%" OR LOWER(efo_term) LIKE "%gout%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828374', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828476', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828510', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828544', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828442', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828306', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828238', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828204', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828578', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828408', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828340', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828272', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1108 | Q34 | What are the names of the genes that are targeted by the drug Tucatinib in the treatment of breast carcinoma? | In the context of breast carcinoma, the drug Tucatinib targets the gene erb-b2 receptor tyrosine kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%tucatinib%" OR LOWER(tradeNames_list) LIKE "%tucatinib%" OR LOWER(syns_list) LIKE "%tucatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924481', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924505', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924509', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924519', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924533', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924537', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924547', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924551', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924495', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924467', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924453', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924449', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924523', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'HER2 Positive Breast Carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924491', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924477', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924463', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.87 | Q34 | What are the names of the genes that are targeted by the drug Pimavanserin Tartrate in the treatment of psychosis? | In the context of psychosis, the drug Pimavanserin Tartrate targets the gene 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%pimavanserin tartrate%" OR LOWER(tradeNames_list) LIKE "%pimavanserin tartrate%" OR LOWER(syns_list) LIKE "%pimavanserin tartrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205117', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205132', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205137', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205142', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205152', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205157', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205162', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205172', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205177', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205182', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205187', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205197', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205202', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205207', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205212', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205217', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205222', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205227', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205232', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205237', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205242', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205247', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205167', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205127', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205107', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205097', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205092', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205192', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205147', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205122', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205112', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_205102', 'drugName': 'Pimavanserin Tartrate', 'tradeNames_list': "['Nuplazid']", 'syns_list': "['ACP-103', 'Pimavanserin tartrate']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1845 | Q34 | What are the names of the genes that are targeted by the drug Simvastatin in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Simvastatin targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%simvastatin%" OR LOWER(tradeNames_list) LIKE "%simvastatin%" OR LOWER(syns_list) LIKE "%simvastatin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103896', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103792', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104104', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104000', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1059 | Q34 | What are the names of the genes that are targeted by the drug Fluorouracil in the treatment of keratosis? | In the context of keratosis, the drug Fluorouracil targets the gene thymidylate synthetase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%keratosis%" OR LOWER(efo_term) LIKE "%keratosis%") AND (LOWER(drugName) LIKE "%fluorouracil%" OR LOWER(tradeNames_list) LIKE "%fluorouracil%" OR LOWER(syns_list) LIKE "%fluorouracil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919465', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919467', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis', 'efo_term': 'keratosis', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1788 | Q34 | What are the names of the genes that are targeted by the drug Dantrolene Sodium in the treatment of Spasticity? | In the context of Spasticity, the drug Dantrolene Sodium targets the gene ryanodine receptor 3 and ryanodine receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spasticity%" OR LOWER(efo_term) LIKE "%spasticity%") AND (LOWER(drugName) LIKE "%dantrolene sodium%" OR LOWER(tradeNames_list) LIKE "%dantrolene sodium%" OR LOWER(syns_list) LIKE "%dantrolene sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100263', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100290', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100299', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100281', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100227', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100218', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100245', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100272', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100254', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100236', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Spasticity', 'efo_term': 'Spasticity', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1801 | Q34 | What are the names of the genes that are targeted by the drug Famotidine in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Famotidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%famotidine%" OR LOWER(tradeNames_list) LIKE "%famotidine%" OR LOWER(syns_list) LIKE "%famotidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100335', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'syns_list': "['Amfamox', 'Fadul', 'Famodil', 'Famosan', 'Famotidine', 'Famoxal', 'GanorGastridin', 'Gastropen', 'L 643341', 'Lecedil', 'MK-208', 'Motiax', 'MucloxNSC-757810', 'Pepcidac', 'Pepdine', 'Pepdul', 'YM-11170']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1762 | Q34 | What are the names of the genes that are targeted by the drug Dexlansoprazole in the treatment of Esophagitis? | In the context of Esophagitis, the drug Dexlansoprazole targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%esophagitis%" OR LOWER(efo_term) LIKE "%esophagitis%") AND (LOWER(drugName) LIKE "%dexlansoprazole%" OR LOWER(tradeNames_list) LIKE "%dexlansoprazole%" OR LOWER(syns_list) LIKE "%dexlansoprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099062', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098702', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098934', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098766', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098622', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099134', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098654', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098686', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098870', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098718', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098950', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098990', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098782', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099094', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098614', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099102', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098630', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099150', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098646', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099158', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098662', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098678', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098838', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098694', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098886', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098710', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098726', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098982', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098742', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098958', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098758', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099006', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098774', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099014', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098790', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099126', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098806', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099086', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098462', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099118', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098518', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099110', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098438', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099190', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098526', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099142', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098470', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099182', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098534', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099174', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099166', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098542', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098822', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098478', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098854', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098550', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098846', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098918', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098558', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098878', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098486', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098910', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098566', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098902', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098430', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099046', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098574', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098942', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098494', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098974', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098582', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098966', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098454', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099038', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098590', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098998', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098502', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099030', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098598', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099022', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098422', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099198', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098606', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099070', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098510', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099214', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099206', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099054', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098926', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098862', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098830', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098814', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098670', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098446', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098894', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098750', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1099078', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098638', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098734', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098798', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Esophagitis', 'efo_term': 'Esophagitis', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1132 | Q34 | What are the names of the genes that are targeted by the drug Trametinib Dimethyl Sulfoxide in the treatment of thyroid cancer? | In the context of thyroid cancer, the drug Trametinib Dimethyl Sulfoxide targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid cancer%" OR LOWER(efo_term) LIKE "%thyroid cancer%") AND (LOWER(drugName) LIKE "%trametinib dimethyl sulfoxide%" OR LOWER(tradeNames_list) LIKE "%trametinib dimethyl sulfoxide%" OR LOWER(syns_list) LIKE "%trametinib dimethyl sulfoxide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927766', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927787', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927794', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927801', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927815', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927822', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927829', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927843', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927850', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927857', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927864', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927878', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927885', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927892', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927899', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927906', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927913', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927920', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927927', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927934', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927941', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927955', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927962', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927969', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927976', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927983', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927997', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928004', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928011', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928018', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928025', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928032', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928039', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928046', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928053', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928060', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928067', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928074', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928081', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928088', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928095', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928102', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928109', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928116', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928123', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928130', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928137', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928144', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928151', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928158', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928165', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928179', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928186', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928193', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928200', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928207', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928214', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928228', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928235', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928242', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928249', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928256', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928263', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928270', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928277', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928284', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928291', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928298', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928305', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928312', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928319', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928326', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928333', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928340', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928347', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928354', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928361', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928368', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928375', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928382', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928389', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928396', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928403', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928410', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928417', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928424', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_928172', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927948', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927836', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927780', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927752', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927738', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927731', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928221', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927990', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927871', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927808', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927773', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927759', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927745', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.364 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of chronic bronchitis? | In the context of chronic bronchitis, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic bronchitis%" OR LOWER(efo_term) LIKE "%chronic bronchitis%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232534', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232615', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232642', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232669', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232723', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232750', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232777', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232831', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232858', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232885', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232912', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232966', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232993', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233020', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233047', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233074', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233101', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233128', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233155', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233182', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233209', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233263', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233290', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233317', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233344', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233371', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233425', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233452', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233479', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233506', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233533', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233560', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233587', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233614', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233641', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233668', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233695', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233722', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233749', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233776', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233803', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233830', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233857', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233884', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233911', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233938', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233965', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233992', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234019', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234046', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234073', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234127', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234154', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234181', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234208', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234235', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234262', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234316', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234343', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234370', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234397', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234424', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234451', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234478', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234505', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234532', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234559', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234586', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234613', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234640', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234667', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234694', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234721', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234748', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234775', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234802', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234829', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234856', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234883', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234910', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234937', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234964', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234991', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235018', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235045', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235072', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234100', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233236', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232804', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232588', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232480', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232426', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232399', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234289', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233398', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232939', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232696', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232561', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232507', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232453', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchitis, Chronic', 'efo_term': 'chronic bronchitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1942 | Q34 | What are the names of the genes that are targeted by the drug Voclosporin in the treatment of immune system disease? | In the context of immune system disease, the drug Voclosporin targets the gene protein phosphatase 3 catalytic subunit alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%voclosporin%" OR LOWER(tradeNames_list) LIKE "%voclosporin%" OR LOWER(syns_list) LIKE "%voclosporin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192226', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'syns_list': "['ISA-247', 'ISA247', 'ISATX-247', 'ISATX247', 'LX-211', 'LX211', 'Voclosporin']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192238', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'syns_list': "['ISA-247', 'ISA247', 'ISATX-247', 'ISATX247', 'LX-211', 'LX211', 'Voclosporin']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1140 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of gastric cancer? | Trametinib has not been approved by the FDA as a treatment for gastric cancer, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastric cancer%" OR LOWER(efo_term) LIKE "%gastric cancer%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928688', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928808', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928848', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928888', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928968', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929008', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929048', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929128', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929168', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929208', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929248', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929328', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929368', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929408', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929448', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929488', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929528', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929568', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929608', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929648', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929688', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929768', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929808', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929848', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929888', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929928', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930008', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930048', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930088', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930128', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930168', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930208', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930248', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930288', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930328', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930368', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930408', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930448', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930488', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930528', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930568', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930608', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930648', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930688', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930728', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930768', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930808', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930848', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930888', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930928', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930968', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931048', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931088', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931128', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931168', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931208', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931248', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931328', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931368', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931408', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931448', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931488', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931528', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931568', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931608', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931648', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931688', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931728', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931768', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931808', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931848', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931888', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931928', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931968', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932008', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932048', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932088', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932128', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932168', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932208', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932248', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932288', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932328', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932368', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932408', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932448', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931008', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929728', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929088', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928768', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928608', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928528', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928488', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931288', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929968', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929288', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928928', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928728', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928648', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928568', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1033 | Q34 | What are the names of the genes that are targeted by the drug Duvelisib in the treatment of chronic lymphocytic leukemia? | In the context of chronic lymphocytic leukemia, the drug Duvelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic lymphocytic leukemia%" OR LOWER(efo_term) LIKE "%chronic lymphocytic leukemia%") AND (LOWER(drugName) LIKE "%duvelisib%" OR LOWER(tradeNames_list) LIKE "%duvelisib%" OR LOWER(syns_list) LIKE "%duvelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858835', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858895', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858915', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858935', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858975', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858995', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859015', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859055', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859075', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859095', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859115', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859155', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859175', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859195', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859215', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859235', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859255', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859275', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859035', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858875', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858795', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858755', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858735', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859135', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858955', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858855', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858815', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858775', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1037 | Q34 | What are the names of the genes that are targeted by the drug Duvelisib in the treatment of neoplasm? | In the context of neoplasm, the drug Duvelisib targets the gene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%duvelisib%" OR LOWER(tradeNames_list) LIKE "%duvelisib%" OR LOWER(syns_list) LIKE "%duvelisib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_858759', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858737', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859119', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858777', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858756', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858779', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858797', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858939', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859079', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858817', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859277', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859159', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858837', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859176', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859179', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858736', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858976', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859177', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858999', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859019', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858877', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858799', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859059', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858897', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859256', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858816', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858917', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859217', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858819', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859139', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858937', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859216', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858836', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859276', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858957', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858979', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858739', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858997', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858977', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858796', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858856', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858839', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858956', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858857', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858859', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859016', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859017', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859199', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858876', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859036', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859037', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858879', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859056', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859057', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859237', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858896', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859076', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859259', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858899', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859096', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859097', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859257', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858916', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859116', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859117', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859197', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858919', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859136', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859137', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859279', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858936', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859196', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858996', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859239', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859236', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859219', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859039', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859156', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859157', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859077', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859099', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858776', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'neoplasm of mature B-cells', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858959', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858757', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859113', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858833', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858933', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859133', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859153', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858953', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859173', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859193', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858793', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858853', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858973', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859213', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_858993', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_858873', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_859013', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}, {'UUID': 'DrugTargetsIndication121923_text_859033', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'syns_list': "['Duvelisib', 'Duvelisib hydrate', 'Duvelisib monohydrate', 'INK-1147INK-1197', 'IPI-145']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1205 | Q34 | What are the names of the genes that are targeted by the drug Albuterol in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Albuterol targets the gene adrenoceptor beta 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%albuterol%" OR LOWER(tradeNames_list) LIKE "%albuterol%" OR LOWER(syns_list) LIKE "%albuterol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936761', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936848', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936877', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936906', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936964', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936993', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936819', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936703', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936645', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936616', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936935', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936790', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936732', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_936674', 'drugName': 'Albuterol', 'tradeNames_list': "['Aerolin', 'Aerolin 400', 'Aerolin auto', 'Airomir', 'Airsalb', 'AlbuterolAsmasal clickhaler', 'Asmasal spacehaler', 'Asmaven', 'AsmaventCobutolin', 'Combivent', 'Combivent udvs', 'Ipramol steri-neb', 'KentamolLibetist', 'Maxivent', 'Proair Hfa', 'Proventil', 'Proventil Hfa', 'RimasalSalamol e-breathe', 'Salapin', 'Salbulin novolizer', 'SalbuventSalipraneb', 'Steri-neb salamol', 'Ventmax sr', 'Ventodisks', 'VentolinVentolin Hfa', 'Ventolin cr', 'Ventolin e-breathe', 'Volmax']", 'syns_list': "['Accuneb', 'Albuterol', 'Combivent', 'Duoneb', 'Etinoline', 'NSC-757417PROVENTIL-HFA', 'SCH 13949W', 'SCH-13949W', 'Salbutamol', 'SalbutamolumVentoline', 'Volmax']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1340 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of Back pain? | In the context of Back pain, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%back pain%" OR LOWER(efo_term) LIKE "%back pain%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993224', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993150', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993076', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993039', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993261', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993187', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993113', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1061 | Q34 | What are the names of the genes that are targeted by the drug Imiquimod in the treatment of actinic keratosis? | In the context of actinic keratosis, the drug Imiquimod targets the gene toll like receptor 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%actinic keratosis%" OR LOWER(efo_term) LIKE "%actinic keratosis%") AND (LOWER(drugName) LIKE "%imiquimod%" OR LOWER(tradeNames_list) LIKE "%imiquimod%" OR LOWER(syns_list) LIKE "%imiquimod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919779', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919938', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919991', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920044', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920150', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920203', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920256', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920309', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919885', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919673', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919567', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919514', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920097', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919832', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919726', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919620', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.670 | Q34 | What are the names of the genes that are targeted by the drug Apremilast in the treatment of Oral ulcer? | In the context of Oral ulcer, the drug Apremilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%oral ulcer%" OR LOWER(efo_term) LIKE "%oral ulcer%") AND (LOWER(drugName) LIKE "%apremilast%" OR LOWER(tradeNames_list) LIKE "%apremilast%" OR LOWER(syns_list) LIKE "%apremilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696931', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697015', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697043', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697071', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697127', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697155', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697183', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697239', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697267', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697295', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697323', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697379', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697407', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697435', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697463', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697491', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697519', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697547', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697575', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697603', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697631', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697687', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697715', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697743', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697771', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697799', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697855', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697883', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697911', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697939', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697967', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697995', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698023', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698051', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698079', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698107', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698135', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698163', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698191', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698219', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698247', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698275', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698303', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698331', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698359', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698387', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698415', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698443', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698471', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698499', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698527', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698583', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698611', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698639', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698667', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698695', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698723', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698779', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698807', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698835', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698863', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698891', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698919', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698947', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698975', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699003', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699031', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699059', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699087', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699115', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699143', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699171', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699199', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699227', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699255', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699283', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699311', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699339', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699367', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699395', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699423', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699451', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699479', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699507', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699535', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699563', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_698555', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697659', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697211', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696987', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696875', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696819', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696791', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698751', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697827', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697351', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697099', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696959', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696903', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696847', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Oral Ulcer', 'efo_term': 'Oral ulcer', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.366 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of asthma? | In the context of asthma, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%asthma%" OR LOWER(efo_term) LIKE "%asthma%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232536', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232617', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232644', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232671', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232725', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232752', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232779', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232833', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232860', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232887', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232914', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232968', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232995', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233022', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233049', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233076', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233103', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233130', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233157', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233184', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233211', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233265', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233292', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233319', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233346', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233373', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233427', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233454', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233481', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233508', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233535', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233562', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233589', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233616', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233643', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233670', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233697', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233724', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233751', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233778', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233805', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233832', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233859', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233886', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233913', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233940', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233967', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233994', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234021', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234048', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234075', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234129', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234156', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234183', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234210', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234237', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234264', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234318', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234345', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234372', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234399', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234426', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234453', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234480', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234507', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234534', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234561', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234588', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234615', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234642', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234669', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234696', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234723', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234750', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234777', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234804', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234831', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234858', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234885', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234912', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234939', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234966', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234993', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235020', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235047', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235074', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234102', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233238', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232806', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232590', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232482', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232428', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232401', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234291', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233400', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232941', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232698', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232563', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232509', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232455', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Asthma', 'efo_term': 'asthma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.79 | Q34 | What are the names of the genes that are targeted by the drug Bromocriptine Mesylate in the treatment of hyperprolactinemia? | In the context of hyperprolactinemia, the drug Bromocriptine Mesylate targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hyperprolactinemia%" OR LOWER(efo_term) LIKE "%hyperprolactinemia%") AND (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_list) LIKE "%bromocriptine mesylate%" OR LOWER(syns_list) LIKE "%bromocriptine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201375', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201396', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201403', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201410', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201424', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201431', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201438', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201452', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201459', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201466', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201473', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201487', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201494', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201501', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201508', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201515', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201522', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201529', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201536', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201543', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201550', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201564', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201571', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201578', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201585', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201592', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201606', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201613', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201620', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201627', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201634', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201641', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201648', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201655', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201662', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201669', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201676', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201683', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201690', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201697', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201704', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201711', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201718', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201725', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201732', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201739', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201746', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201753', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201760', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201767', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201774', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201788', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201795', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201802', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201809', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201816', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201823', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201837', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201844', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201851', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201858', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201865', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201872', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201879', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201886', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201893', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201900', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201907', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201914', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201921', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201928', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201935', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201942', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201949', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201956', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201963', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201970', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201977', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201984', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201991', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201998', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202005', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202012', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202019', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202026', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202033', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201781', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201557', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201445', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201389', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201361', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201347', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201340', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201830', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201599', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201480', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201417', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201382', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201368', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201354', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperprolactinemia', 'efo_term': 'hyperprolactinemia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.28 | Q34 | What are the names of the genes that are targeted by the drug Brexpiprazole in the treatment of schizophrenia? | In the context of schizophrenia, the drug Brexpiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%brexpiprazole%" OR LOWER(tradeNames_list) LIKE "%brexpiprazole%" OR LOWER(syns_list) LIKE "%brexpiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155835', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155877', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155891', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155905', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155933', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155947', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155961', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155989', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156003', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156017', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156031', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156059', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156073', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156087', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156101', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156115', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156129', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156143', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156157', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156171', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156185', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156213', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156227', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156241', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156255', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156269', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156297', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156311', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156325', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156339', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156353', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156367', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156381', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156395', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156409', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156423', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156437', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156451', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156465', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156479', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156493', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156507', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156521', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156535', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156549', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156563', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156577', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156591', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156605', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156619', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156633', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156661', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156675', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156689', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156703', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156717', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156731', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156759', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156773', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156787', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156801', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156815', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156829', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156843', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156857', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156871', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156885', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156899', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156913', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156927', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156941', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156955', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156969', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156983', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156997', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157011', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157025', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157039', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157053', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157067', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157081', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157095', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157109', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157123', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157137', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_157151', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156647', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156199', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155975', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155863', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155807', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155779', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155765', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156745', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_156283', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_156045', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155919', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155849', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155821', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_155793', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'syns_list': "['Brexpiprazole', 'OPC-34712']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1725 | Q34 | What are the names of the genes that are targeted by the drug Tafamidis in the treatment of cardiomyopathy? | In the context of cardiomyopathy, the drug Tafamidis targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiomyopathy%" OR LOWER(efo_term) LIKE "%cardiomyopathy%") AND (LOWER(drugName) LIKE "%tafamidis%" OR LOWER(tradeNames_list) LIKE "%tafamidis%" OR LOWER(syns_list) LIKE "%tafamidis%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097615', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097629', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097634', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097639', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097607', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097599', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097595', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097624', 'drugName': 'Tafamidis Meglumine', 'tradeNames_list': "['Vyndaqel']", 'syns_list': "['FX-1006A', 'Tafamidis meglumine']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097619', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097611', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097603', 'drugName': 'Tafamidis', 'tradeNames_list': "['Vyndamax', 'Vyndaqel']", 'syns_list': "['FX-1005', 'FX-1006', 'FX1006', 'Tafamidis']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathies', 'efo_term': 'cardiomyopathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.529 | Q34 | What are the names of the genes that are targeted by the drug Cetirizine Hydrochloride in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Cetirizine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%cetirizine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cetirizine hydrochloride%" OR LOWER(syns_list) LIKE "%cetirizine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455806', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455814', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455816', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455819', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455824', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455826', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455829', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455834', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455836', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455839', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455841', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455846', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455993', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'syns_list': "['Cetirizine (r)-form dihydrochloride', 'Cetirizine hydrochloride (r)-Levocetirizine dihydrochloride', 'Levocetirizine hydrochlorideLevocetirizine monohydrochloride', 'NSC-758898', 'UCB 28556', 'UCB-28556']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455831', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455811', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455801', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455796', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455794', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455844', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455821', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455809', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455804', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455799', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1818 | Q34 | What are the names of the genes that are targeted by the drug Viltolarsen in the treatment of Duchenne muscular dystrophy? | In the context of Duchenne muscular dystrophy, the drug Viltolarsen targets the gene dystrophin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%duchenne muscular dystrophy%" OR LOWER(efo_term) LIKE "%duchenne muscular dystrophy%") AND (LOWER(drugName) LIKE "%viltolarsen%" OR LOWER(tradeNames_list) LIKE "%viltolarsen%" OR LOWER(syns_list) LIKE "%viltolarsen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100428', 'drugName': 'Viltolarsen', 'tradeNames_list': "['Viltepso']", 'syns_list': "['NCNP-01', 'NS-065', 'NS-065/NCNP-01', 'Ns-065/ncnp-01', 'Viltolarsen']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100430', 'drugName': 'Viltolarsen', 'tradeNames_list': "['Viltepso']", 'syns_list': "['NCNP-01', 'NS-065', 'NS-065/NCNP-01', 'Ns-065/ncnp-01', 'Viltolarsen']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.56 | Q34 | What are the names of the genes that are targeted by the drug Lurasidone Hydrochloride in the treatment of bipolar disorder? | In the context of bipolar disorder, the drug Lurasidone Hydrochloride targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar disorder%" OR LOWER(efo_term) LIKE "%bipolar disorder%") AND (LOWER(drugName) LIKE "%lurasidone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%lurasidone hydrochloride%" OR LOWER(syns_list) LIKE "%lurasidone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197905', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197910', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197911', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197913', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197916', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197917', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197919', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197922', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197923', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197925', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197926', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197929', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197931', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197932', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197934', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197935', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197937', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197938', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197940', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197941', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197943', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197946', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197947', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197949', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197950', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197952', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197955', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197956', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197958', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197959', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197961', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197962', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197964', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197965', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197967', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197968', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197970', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197971', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197973', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197974', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197976', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197977', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197979', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197980', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197982', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197983', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197985', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197986', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197988', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197989', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197991', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197994', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197995', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197997', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197998', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198000', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198001', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198004', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198006', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198007', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198009', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198010', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198012', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198013', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198015', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198016', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198018', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198019', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198021', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198022', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198024', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198025', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198027', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198028', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198030', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198031', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198033', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198034', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198036', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198037', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198039', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198040', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198042', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198043', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198045', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198046', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197992', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197944', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197920', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197908', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197902', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197899', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197898', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198003', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197953', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197928', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197914', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197907', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197904', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197901', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.643 | Q34 | What are the names of the genes that are targeted by the drug Lenvatinib Mesylate in the treatment of thyroid cancer? | In the context of thyroid cancer, the drug Lenvatinib Mesylate targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid cancer%" OR LOWER(efo_term) LIKE "%thyroid cancer%") AND (LOWER(drugName) LIKE "%lenvatinib mesylate%" OR LOWER(tradeNames_list) LIKE "%lenvatinib mesylate%" OR LOWER(syns_list) LIKE "%lenvatinib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_690184', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690214', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690224', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690234', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690254', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690264', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690274', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690294', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690304', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690314', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690324', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690344', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690354', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690364', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690374', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690384', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690394', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690404', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690414', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690424', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690434', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690454', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690464', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690474', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690484', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690444', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690204', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690164', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690144', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690134', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690284', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690334', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690244', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690194', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690174', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690154', 'drugName': 'Lenvatinib Mesylate', 'tradeNames_list': "['Lenvima']", 'syns_list': "['E-7080 MESYLATE', 'E7080', 'E7080 MESYLATE', 'Lenvatinib mesilateLenvatinib mesylate', 'Lenvatinib methanesulfonate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.304 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of psoriatic arthritis? | In the context of psoriatic arthritis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriatic arthritis%" OR LOWER(efo_term) LIKE "%psoriatic arthritis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227759', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228614', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228899', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229184', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229754', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230039', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230324', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230894', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231179', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231464', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231749', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232319', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230609', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228329', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227189', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226619', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226334', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232034', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229469', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228044', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227474', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226904', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.723 | Q34 | What are the names of the genes that are targeted by the drug Encorafenib in the treatment of neoplasm? | In the context of neoplasm, the drug Encorafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%encorafenib%" OR LOWER(tradeNames_list) LIKE "%encorafenib%" OR LOWER(syns_list) LIKE "%encorafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752291', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752531', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752613', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752669', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752249', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752419', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752237', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752333', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752517', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752375', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752627', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752235', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752629', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752417', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752389', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752461', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752585', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752615', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752601', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752487', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752347', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752447', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752475', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752363', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752545', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752529', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752335', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752657', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752305', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752587', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752265', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752377', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752403', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752643', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752405', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752503', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752655', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752319', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752277', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752671', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752573', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752559', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752307', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752321', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752279', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752515', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752543', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752489', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752293', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752361', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752349', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752433', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752641', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752599', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752501', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752473', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752445', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752557', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752459', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752571', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752251', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752431', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752391', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752263', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752396', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752397', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752245', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752268', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752312', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752402', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752313', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752270', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752408', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752410', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752413', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752318', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752229', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752248', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752271', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752416', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752422', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752273', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752411', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752315', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752324', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752326', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752276', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752327', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752399', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752329', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752332', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752254', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752282', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752338', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752340', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752341', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752284', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752343', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752346', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752285', 'drugName': 'Encorafenib', 'tradeNames_list': "['Braftovi']", 'syns_list': "['Encorafenib', 'Lgx-818', 'Lgx818', 'NVP-LGX-818-NXA', 'NVP-LGX818NVP-LGX818-NXA']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.629 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib Tosylate in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Sorafenib Tosylate targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%sorafenib tosylate%" OR LOWER(tradeNames_list) LIKE "%sorafenib tosylate%" OR LOWER(syns_list) LIKE "%sorafenib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_683296', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683357', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683414', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683416', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683475', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683477', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683479', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683538', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683540', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683597', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683599', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683658', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683660', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683662', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683719', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683721', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683723', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683780', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683782', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683784', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683841', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683845', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683902', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683904', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683906', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683963', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683967', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684024', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684026', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684028', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684085', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684087', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684089', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684146', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684148', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684150', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684207', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684209', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684211', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684268', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684270', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684272', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684329', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684331', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684333', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684390', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684392', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684394', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684451', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684453', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684455', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684514', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684516', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684573', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684575', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684577', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684634', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684638', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684695', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684697', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684699', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684756', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684758', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684760', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684817', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684819', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684821', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684878', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684880', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684882', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684939', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684941', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684943', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685000', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685002', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685004', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685061', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685063', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685065', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685122', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685124', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685126', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685183', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685185', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685187', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685244', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684512', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683843', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683536', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683355', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683292', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683233', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683231', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_684636', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683965', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683601', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683418', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683353', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'chromophobe renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683294', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683235', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.8 | Q34 | What are the names of the genes that are targeted by the drug Risperidone in the treatment of aggressive behavior? | In the context of aggressive behavior, the drug Risperidone targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%aggressive behavior%" OR LOWER(efo_term) LIKE "%aggressive behavior%") AND (LOWER(drugName) LIKE "%risperidone%" OR LOWER(tradeNames_list) LIKE "%risperidone%" OR LOWER(syns_list) LIKE "%risperidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149653', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149752', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149785', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149818', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149884', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149917', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149950', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150016', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150049', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150082', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150115', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150181', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150214', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150247', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150280', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150313', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150346', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150379', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150412', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150445', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150478', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150544', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150577', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150610', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150643', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150676', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150742', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150775', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150808', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150841', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150874', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150907', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150940', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150973', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151006', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151039', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151072', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151105', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151138', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151171', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151204', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151237', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150511', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149983', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149719', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149587', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149521', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149488', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150709', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150148', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149851', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149686', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149620', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149554', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Aggression', 'efo_term': 'aggressive behavior', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.809 | Q34 | What are the names of the genes that are targeted by the drug Balsalazide Disodium in the treatment of ulcerative colitis? | In the context of ulcerative colitis, the drug Balsalazide Disodium targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, peroxisome proliferator activated receptor gamma and arachidonate 5-lipoxygenase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ulcerative colitis%" OR LOWER(efo_term) LIKE "%ulcerative colitis%") AND (LOWER(drugName) LIKE "%balsalazide disodium%" OR LOWER(tradeNames_list) LIKE "%balsalazide disodium%" OR LOWER(syns_list) LIKE "%balsalazide disodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828148', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828151', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828152', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828153', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828155', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828156', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828157', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828159', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828160', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828161', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828162', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828164', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828165', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828166', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828167', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828168', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828169', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828170', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828171', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828172', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828173', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828174', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'ALOX5', 'approvedName': 'arachidonate 5-lipoxygenase'}, {'UUID': 'DrugTargetsIndication121923_text_828158', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828150', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828146', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828144', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828143', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828163', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PPARG', 'approvedName': 'peroxisome proliferator activated receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_828154', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828149', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828147', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828145', 'drugName': 'Balsalazide Disodium', 'tradeNames_list': "['Balsalazide disodium', 'Colazal', 'Colazide', 'Giazo']", 'syns_list': "['BX-661A', 'BX661A', 'Balsalazide disodiumBalsalazide disodium anhydrous', 'Balsalazide disodium dihydrateBalsalazide disodium salt dihydrate', 'Balsalazide sodium', 'BalsalazineNSC-760046']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colitis, Ulcerative', 'efo_term': 'ulcerative colitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1056 | Q34 | What are the names of the genes that are targeted by the drug Fluorouracil in the treatment of neoplasm? | In the context of neoplasm, the drug Fluorouracil targets the gene thymidylate synthetase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%fluorouracil%" OR LOWER(tradeNames_list) LIKE "%fluorouracil%" OR LOWER(syns_list) LIKE "%fluorouracil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919463', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919464', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919404', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919427', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919437', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Inflammatory Breast Neoplasms', 'efo_term': 'inflammatory breast carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919402', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919401', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'bladder tumor', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919421', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Nasopharyngeal Neoplasms', 'efo_term': 'nasopharyngeal neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919426', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pharyngeal Neoplasms', 'efo_term': 'pharynx cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919413', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Laryngeal Neoplasms', 'efo_term': 'laryngeal neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919410', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919397', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919449', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919444', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919416', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Paranasal Sinus Neoplasms', 'efo_term': 'paranasal sinus neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919455', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms, Hereditary Nonpolyposis', 'efo_term': 'Lynch syndrome', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919418', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Biliary Tract Neoplasms', 'efo_term': 'biliary tract neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919419', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'stomach neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919420', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919428', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal squamous cell carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919454', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919423', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'colonic neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919425', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Mouth Neoplasms', 'efo_term': 'oral cavity cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919411', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919430', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919412', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypopharyngeal Neoplasms', 'efo_term': 'hypopharyngeal carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919432', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urothelial carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919414', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anus Neoplasms', 'efo_term': 'anal neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919457', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'esophageal cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919439', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'neuroendocrine neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919441', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919443', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919458', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colonic Neoplasms', 'efo_term': 'malignant colon neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919445', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anus Neoplasms', 'efo_term': 'anus cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919446', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919448', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Laryngeal Neoplasms', 'efo_term': 'laryngeal carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919453', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Anus Neoplasms', 'efo_term': 'anal carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919450', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919451', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919452', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Biliary Tract Neoplasms', 'efo_term': 'biliary tract cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919456', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919461', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectal carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919429', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck neoplasia', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919405', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Stomach Neoplasms', 'efo_term': 'gastric adenocarcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919422', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919435', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Rectal Neoplasms', 'efo_term': 'rectum cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919433', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919459', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Esophageal Neoplasms', 'efo_term': 'neoplasm of esophagus', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919415', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919417', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919379', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919385', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919392', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Digestive System Neoplasms', 'efo_term': 'digestive system cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919393', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bile Duct Neoplasms', 'efo_term': 'bile duct cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919387', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneal neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919384', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Digestive System Neoplasms', 'efo_term': 'digestive system neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919394', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Urethral Neoplasms', 'efo_term': 'urethra cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919395', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919382', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919391', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_919376', 'drugName': 'Fluorouracil', 'tradeNames_list': "['5.f.u.', 'Accusite', 'Actikerall', 'Adrucil', 'Carac', 'Efudex', 'EfudixFluoro-uracil roche', 'Fluoroplex', 'Fluorouracil', 'Tolak']", 'syns_list': "['5 FU', '5-FU', '5-Fluorouracil', '5-fluoruracil', 'FluorouracilFluorouracilum', 'Fluorouricil', 'Fluracil', 'NSC-19893', 'PhthoruracilQueroplex', 'RO 2-9757', 'RO-2-9757', 'RO-29757']", 'yearOfFirstApproval': 1962, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.338 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of subacute thyroiditis? | In the context of subacute thyroiditis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%subacute thyroiditis%" OR LOWER(efo_term) LIKE "%subacute thyroiditis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227794', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228649', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228934', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229219', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229789', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230074', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230359', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230929', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231214', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231499', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231784', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232354', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230644', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228364', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227224', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226654', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226369', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232069', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229504', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228079', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227509', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226939', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.48 | Q34 | What are the names of the genes that are targeted by the drug Paliperidone Palmitate in the treatment of schizoaffective disorder? | In the context of schizoaffective disorder, the drug Paliperidone Palmitate targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizoaffective disorder%" OR LOWER(efo_term) LIKE "%schizoaffective disorder%") AND (LOWER(drugName) LIKE "%paliperidone palmitate%" OR LOWER(tradeNames_list) LIKE "%paliperidone palmitate%" OR LOWER(syns_list) LIKE "%paliperidone palmitate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197438', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197444', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197446', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197448', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197452', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197454', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197456', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197460', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197462', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197464', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197466', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197470', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197472', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197474', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197476', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197478', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197480', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197482', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197484', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197486', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197488', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197492', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197494', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197496', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197498', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197500', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197504', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197506', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197508', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197510', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197512', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197514', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197516', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197518', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197520', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197522', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197524', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197526', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197528', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197530', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197532', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197534', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197536', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197538', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197540', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197542', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197544', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197546', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197548', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197550', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197552', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197554', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197490', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197458', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197442', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197434', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197430', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197428', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197502', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197468', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197450', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197440', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197436', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197432', 'drugName': 'Paliperidone Palmitate', 'tradeNames_list': "['Invega hafyera', 'Invega sustenna', 'Invega trinza']", 'syns_list': "['JNS-010', 'JNS010', 'Paliperidone palmitate', 'Palperidone palmitateR-092670', 'R092670', 'RO-92670', 'RO92670']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1466 | Q34 | What are the names of the genes that are targeted by the drug Adapalene in the treatment of acne? | In the context of acne, the drug Adapalene targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%adapalene%" OR LOWER(tradeNames_list) LIKE "%adapalene%" OR LOWER(syns_list) LIKE "%adapalene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055563', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055569', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055571', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055573', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055577', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055579', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055581', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055585', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055587', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055589', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055591', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055595', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055597', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055599', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055601', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055603', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055605', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055583', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055567', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055559', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055555', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055553', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055593', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055575', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055565', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055561', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055557', 'drugName': 'Adapalene', 'tradeNames_list': "['Adapalene', 'Differin']", 'syns_list': "['Adapalene', 'CD 271', 'CD-271', 'Differin']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.108 | Q34 | What are the names of the genes that are targeted by the drug Ondansetron in the treatment of Radiation-induced nausea and vomiting? | In the context of Radiation-induced nausea and vomiting, the drug Ondansetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%radiation-induced nausea and vomiting%" OR LOWER(efo_term) LIKE "%radiation-induced nausea and vomiting%") AND (LOWER(drugName) LIKE "%ondansetron%" OR LOWER(tradeNames_list) LIKE "%ondansetron%" OR LOWER(syns_list) LIKE "%ondansetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205903', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205863', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205983', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205943', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.351 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency? | In the context of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency%" OR LOWER(efo_term) LIKE "%classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227807', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228662', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228947', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229232', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229802', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230087', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230372', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230942', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231227', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231512', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231797', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232367', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230657', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228377', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227237', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226667', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226382', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232082', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229517', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228092', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227522', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226952', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.240 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of skin disease? | In the context of skin disease, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin disease%" OR LOWER(efo_term) LIKE "%skin disease%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222200', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222330', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222070', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221940', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221875', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222265', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222135', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222005', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.215 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency? | In the context of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency%" OR LOWER(efo_term) LIKE "%classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218721', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219345', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219553', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219761', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220177', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220385', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220593', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220801', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219137', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218305', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217889', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217681', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219969', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218929', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218513', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218097', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenal Hyperplasia, Congenital', 'efo_term': 'classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1239 | Q34 | What are the names of the genes that are targeted by the drug Vibegron in the treatment of Urinary incontinence? | In the context of Urinary incontinence, the drug Vibegron targets the gene adrenoceptor beta 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urinary incontinence%" OR LOWER(efo_term) LIKE "%urinary incontinence%") AND (LOWER(drugName) LIKE "%vibegron%" OR LOWER(tradeNames_list) LIKE "%vibegron%" OR LOWER(syns_list) LIKE "%vibegron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938260', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938259', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938265', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938264', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence', 'efo_term': 'Urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1126 | Q34 | What are the names of the genes that are targeted by the drug Binimetinib in the treatment of metastatic melanoma? | In the context of metastatic melanoma, the drug Binimetinib targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic melanoma%" OR LOWER(efo_term) LIKE "%metastatic melanoma%") AND (LOWER(drugName) LIKE "%binimetinib%" OR LOWER(tradeNames_list) LIKE "%binimetinib%" OR LOWER(syns_list) LIKE "%binimetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_926785', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926863', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926889', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926915', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926967', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926993', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927019', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927071', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927097', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927123', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927149', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926837', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926733', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926681', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926655', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927045', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926941', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926811', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926759', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926707', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.799 | Q34 | What are the names of the genes that are targeted by the drug Ospemifene in the treatment of Dyspareunia? | In the context of Dyspareunia, the drug Ospemifene targets the gene estrogen receptor 1 and estrogen receptor 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dyspareunia%" OR LOWER(efo_term) LIKE "%dyspareunia%") AND (LOWER(drugName) LIKE "%ospemifene%" OR LOWER(tradeNames_list) LIKE "%ospemifene%" OR LOWER(syns_list) LIKE "%ospemifene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823746', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823758', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823762', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823766', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823774', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823778', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823782', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823790', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823794', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823798', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823802', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823810', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823814', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823818', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823822', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823826', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823830', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823834', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823838', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823842', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823846', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823854', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823858', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823862', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823866', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823870', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823850', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823786', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823754', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823738', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823730', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823726', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823874', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823806', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_823770', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823750', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823742', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823734', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'syns_list': "['(deaminohydroxy) toremifene', 'FC-1271', 'FC-1271A', 'OspemifeneTore iii']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyspareunia', 'efo_term': 'Dyspareunia', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1111 | Q34 | What are the names of the genes that are targeted by the drug Tucatinib in the treatment of brain neoplasm? | In the context of brain neoplasm, the drug Tucatinib targets the gene erb-b2 receptor tyrosine kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%brain neoplasm%" OR LOWER(efo_term) LIKE "%brain neoplasm%") AND (LOWER(drugName) LIKE "%tucatinib%" OR LOWER(tradeNames_list) LIKE "%tucatinib%" OR LOWER(syns_list) LIKE "%tucatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924522', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924550', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924494', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924466', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924452', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924536', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924508', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924480', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1568 | Q34 | What are the names of the genes that are targeted by the drug Sirolimus in the treatment of eye disease? | In the context of eye disease, the drug Sirolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye disease%" OR LOWER(efo_term) LIKE "%eye disease%") AND (LOWER(drugName) LIKE "%sirolimus%" OR LOWER(tradeNames_list) LIKE "%sirolimus%" OR LOWER(syns_list) LIKE "%sirolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084564', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084429', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084834', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084699', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'syns_list': "['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1767 | Q34 | What are the names of the genes that are targeted by the drug Risedronate Sodium in the treatment of osteoporosis? | In the context of osteoporosis, the drug Risedronate Sodium targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoporosis%" OR LOWER(efo_term) LIKE "%osteoporosis%") AND (LOWER(drugName) LIKE "%risedronate sodium%" OR LOWER(tradeNames_list) LIKE "%risedronate sodium%" OR LOWER(syns_list) LIKE "%risedronate sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099441', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099454', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099455', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099461', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099468', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099469', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099448', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099434', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099427', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099426', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099462', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099447', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099440', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099433', 'drugName': 'Risedronate Sodium', 'tradeNames_list': "['Actonel', 'Atelvia', 'Risedronate sodium']", 'syns_list': "['NE-58095', 'NE-58095 ANHYDROUS', 'NSC-722598', 'NSC-759280Risedronate monosodium', 'Risedronate sodiumRisedronate sodium anhydrous', 'Risedronic acid monosodium salt']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.527 | Q34 | What are the names of the genes that are targeted by the drug Cetirizine Hydrochloride in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Cetirizine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%cetirizine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cetirizine hydrochloride%" OR LOWER(syns_list) LIKE "%cetirizine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455819', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455834', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455839', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455844', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455829', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455809', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455799', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455794', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455993', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'syns_list': "['Cetirizine (r)-form dihydrochloride', 'Cetirizine hydrochloride (r)-Levocetirizine dihydrochloride', 'Levocetirizine hydrochlorideLevocetirizine monohydrochloride', 'NSC-758898', 'UCB 28556', 'UCB-28556']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455824', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455814', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455804', 'drugName': 'Cetirizine Hydrochloride', 'tradeNames_list': '[\'Allacan\', \'Allertek\', \'Becoallergy\', \'Cetec\', \'Cetirizine hydrochlorideCetirizine hydrochloride allergy\', \'Cetirizine hydrochloride hivesCetirizine hydrochloride hives relief\', "CetirocolChildren\'s cetirizine hydrochloride allergyChildren\'s cetirizine hydrochloride hives reliefChildren\'s zyrtec allergyChildren\'s zyrtec hives reliefPiritezePollenshield", \'Quzyttir\', \'Zerviate\', \'Ziralton\', \'Zirtek\', \'Zynor\', \'ZyrtecZyrtec allergy\', \'Zyrtec hives relief\']', 'syns_list': "['Cetirizine', 'Cetirizine dihydrochloride', 'Cetirizine hclCetirizine hydrochloride', 'Cetrine', 'NSC-759102', 'P 071', 'P-071Zyrtec']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.234 | Q34 | What are the names of the genes that are targeted by the drug Beclomethasone Dipropionate in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Beclomethasone Dipropionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%beclomethasone dipropionate%" OR LOWER(tradeNames_list) LIKE "%beclomethasone dipropionate%" OR LOWER(syns_list) LIKE "%beclomethasone dipropionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_220953', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220976', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220997', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220998', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221020', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221021', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221022', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221044', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221045', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221066', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221067', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221089', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221090', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221091', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221112', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221113', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221114', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221135', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221136', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221137', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221158', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221160', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221181', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221182', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221183', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221204', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221206', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221227', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221228', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221229', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221250', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221251', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221252', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221273', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221274', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221275', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221296', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221297', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221298', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221319', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221320', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221321', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221342', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221343', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221344', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221365', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221366', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221367', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221388', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221389', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221390', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221412', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221413', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221434', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221435', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221436', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221457', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221459', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221480', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221481', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221482', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221503', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221504', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221505', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221526', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221527', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221528', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221549', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221550', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221551', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221572', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221573', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221574', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221595', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221596', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221597', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221618', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221619', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221620', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221641', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221642', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221643', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221664', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221665', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221666', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221687', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221411', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221159', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221043', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220975', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220951', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220929', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220928', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221458', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221205', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221068', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220999', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220974', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220952', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220930', 'drugName': 'Beclomethasone Dipropionate', 'tradeNames_list': "['Aerobec 100', 'Aerobec 50', 'Aerobec fte 250', 'Asmabec clickhalerAsmabec spacehaler', 'Beclazone 100', 'Beclazone 100 e-breatheBeclazone 200', 'Beclazone 250', 'Beclazone 250 e-breathe', 'Beclazone 50Beclazone 50 e-breathe', 'Becloaqua 50', 'BecloforteBecloforte e-breathe', 'Becloforte integra', 'Becloforte-vmBeclomet diprop', 'Beclomet hayfever', 'Beclomist', 'BeclotaideBeclovent', 'Becodisks', 'Beconase', 'Beconase aq', 'BecotideBecotide 100', 'Becotide 100 e-breathe', 'Becotide 200', 'Becotide 50Becotide 50 e-breathe', 'Clenil modulite', 'Clipper', 'Filair 100Filair 50', 'Filair fte', 'Fostair', 'Fostair nexthaler', 'Nasobec aqNasobec hayfever', 'Propaderm', 'Propaderm fte', 'Propaderm-aPropaderm-c', 'Pulvinal beclomet', 'Qnasl', 'Qvar 100', 'Qvar 100 e-breatheQvar 40', 'Qvar 50', 'Qvar 50 e-breathe', 'Qvar 80', 'Qvar redihalerRino clenil', 'Vancenase', 'Vancenase aq', 'Vancenase pockethalerVanceril', 'Vanceril double strength', 'Ventide', 'VivabecZonivent aquanasal']", 'syns_list': "['Beclometasone', 'Beclometasone dipropionate', 'BeclomethasoneBeclomethasone dipropionate', 'Beclomethasone dipropionate monohydrateNSC-755901', 'SCH 18020W', 'SCH 8020W', 'SCH-18020W', 'SGX-201', 'SGX-202SGX-203']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.649 | Q34 | What are the names of the genes that are targeted by the drug Vasopressin in the treatment of Sepsis? | In the context of Sepsis, the drug Vasopressin targets the gene arginine vasopressin receptor 2, arginine vasopressin receptor 1A and arginine vasopressin receptor 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sepsis%" OR LOWER(efo_term) LIKE "%sepsis%") AND (LOWER(drugName) LIKE "%vasopressin%" OR LOWER(tradeNames_list) LIKE "%vasopressin%" OR LOWER(syns_list) LIKE "%vasopressin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_692606', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692660', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692678', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692696', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692732', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692750', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692768', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692804', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692822', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692840', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692858', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692894', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692912', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692930', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692948', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692966', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692984', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693002', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693020', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693038', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693056', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693092', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693110', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693128', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693146', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693164', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693200', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693218', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693236', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693254', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693272', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693290', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693308', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693326', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693344', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693362', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693380', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693398', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693416', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693434', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693452', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693470', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693488', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693506', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693524', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693542', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693560', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693578', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693596', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693614', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693632', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693668', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693686', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693704', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693722', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693740', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693758', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693794', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693812', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693830', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693848', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693866', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693884', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693902', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693920', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693938', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693956', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693974', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693992', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694010', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694028', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694046', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694064', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694082', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694100', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694118', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694136', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694154', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694172', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694190', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694208', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694226', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694244', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694262', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694280', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694298', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693650', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_693074', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692786', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692642', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692570', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692534', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692516', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_693776', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_693182', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_692876', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692714', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692624', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692588', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_692552', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'syns_list': "['Arginine Vasopressin', 'Arginine vasopressin', 'Argipressin or lypressinVasopressin', 'Vasopressin injection', 'Vasopressin, unspecified']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1494 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of leptomeningeal metastasis? | In the context of leptomeningeal metastasis, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%leptomeningeal metastasis%" OR LOWER(efo_term) LIKE "%leptomeningeal metastasis%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057595', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058078', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058239', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058400', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058722', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058883', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059044', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059366', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059527', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059688', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059849', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060171', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060332', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060493', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060654', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060815', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060976', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061137', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061298', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061459', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061620', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061942', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062103', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062264', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062425', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062586', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062908', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063069', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063230', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063391', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063552', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063713', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063874', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064035', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064196', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064357', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064518', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064679', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064840', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065001', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065162', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065323', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065484', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065645', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065806', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1065967', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066128', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066289', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066450', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066611', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066772', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067094', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067255', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067416', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067577', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067738', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1067899', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068221', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068382', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068543', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068704', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068865', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069026', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069187', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069348', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069509', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069670', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069831', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1069992', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070153', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070314', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070475', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070636', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070797', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1070958', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071119', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071280', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071441', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071602', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071763', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1071924', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072085', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072246', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072407', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1066933', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061781', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059205', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057917', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057273', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056951', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056790', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1068060', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062747', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060010', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058561', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057756', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057434', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057112', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.537 | Q34 | What are the names of the genes that are targeted by the drug Alcaftadine in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Alcaftadine targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%alcaftadine%" OR LOWER(tradeNames_list) LIKE "%alcaftadine%" OR LOWER(syns_list) LIKE "%alcaftadine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455861', 'drugName': 'Alcaftadine', 'tradeNames_list': "['Lastacaft']", 'syns_list': "['Alcaftadine', 'R 89674', 'R-89674']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455863', 'drugName': 'Alcaftadine', 'tradeNames_list': "['Lastacaft']", 'syns_list': "['Alcaftadine', 'R 89674', 'R-89674']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1969 | Q34 | What are the names of the genes that are targeted by the drug Topotecan Hydrochloride in the treatment of carcinoma? | In the context of carcinoma, the drug Topotecan Hydrochloride targets the gene DNA topoisomerase I mitochondrial. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%carcinoma%" OR LOWER(efo_term) LIKE "%carcinoma%") AND (LOWER(drugName) LIKE "%topotecan hydrochloride%" OR LOWER(tradeNames_list) LIKE "%topotecan hydrochloride%" OR LOWER(syns_list) LIKE "%topotecan hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193650', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193644', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193574', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193645', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193578', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193579', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'malignant epithelial tumor of ovary', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193572', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193576', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Small Cell', 'efo_term': 'small cell carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193651', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Ovarian Epithelial', 'efo_term': 'malignant epithelial tumor of ovary', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193573', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193646', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193648', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Small Cell', 'efo_term': 'small cell carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193636', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193561', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical adenocarcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193563', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193633', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical adenocarcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193564', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'Fallopian Tube Carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193632', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193635', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193560', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193537', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193609', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193510', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Endometrioid', 'efo_term': 'endometrioid carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193514', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193586', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193596', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193524', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}, {'UUID': 'DrugTargetsIndication121923_text_1193582', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': "['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']", 'syns_list': "['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Endometrioid', 'efo_term': 'endometrioid carcinoma', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.608 | Q34 | What are the names of the genes that are targeted by the drug Bupivacaine in the treatment of Hernia? | In the context of Hernia, the drug Bupivacaine targets the gene sodium voltage-gated channel alpha subunit 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hernia%" OR LOWER(efo_term) LIKE "%hernia%") AND (LOWER(drugName) LIKE "%bupivacaine%" OR LOWER(tradeNames_list) LIKE "%bupivacaine%" OR LOWER(syns_list) LIKE "%bupivacaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_663605', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663673', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662789', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663537', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663265', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663061', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663401', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662857', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662925', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663809', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663469', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_664013', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663333', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663129', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663197', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662993', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663877', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663741', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663945', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hernia', 'efo_term': 'Hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663170', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662966', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663238', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663646', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663714', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663782', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662830', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663034', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663850', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663918', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663306', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663374', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663442', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663578', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662898', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662762', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663102', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663510', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663986', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662733', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662801', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663073', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663141', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663549', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662937', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663617', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663685', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663209', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663753', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663481', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662869', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663005', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663277', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663821', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663889', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663957', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663345', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_664020', 'drugName': 'Bupivacaine Hydrochloride', 'tradeNames_list': "['Bupivac hcl', 'Bupivacaine hydrochloride', 'Bupivacaine hydrochloride kitBupivacaine hydrochloride preservative free', 'Marcain', 'MarcaineMarcaine hydrochloride', 'Marcaine hydrochloride preservative freeSensorcaine', 'Xaracoll']", 'syns_list': "['AH-2250', 'Bupivacaine hcl', 'Bupivacaine hydrochlorideBupivacaine hydrochloride hydrateBupivacaine hydrochloride monohydrate', 'Bupivacaine hydrochloride rsBupivacaini hydrochloridum', 'Carbostesin', 'LAC-43', 'NSC-758631WIN 11,318', 'WIN-11318', 'Xaracoll']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Inguinal', 'efo_term': 'Inguinal hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663413', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hernia, Umbilical', 'efo_term': 'Umbilical hernia', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1872 | Q34 | What are the names of the genes that are targeted by the drug Lenalidomide in the treatment of Mantle cell lymphoma? | In the context of Mantle cell lymphoma, the drug Lenalidomide targets the gene cereblon, damage specific DNA binding protein 1, cullin 4A and ring-box 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mantle cell lymphoma%" OR LOWER(efo_term) LIKE "%mantle cell lymphoma%") AND (LOWER(drugName) LIKE "%lenalidomide%" OR LOWER(tradeNames_list) LIKE "%lenalidomide%" OR LOWER(syns_list) LIKE "%lenalidomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1106173', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106434', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106521', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106608', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106782', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106869', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106956', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107130', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107217', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107304', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107391', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107565', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107652', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107739', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107826', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107913', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108000', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108087', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108174', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108261', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108348', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108522', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108609', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108696', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108783', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108870', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109044', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109131', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109218', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109305', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109392', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109479', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109566', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109653', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109740', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109827', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109914', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110001', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110088', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110175', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110262', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110349', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110436', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110523', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110610', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110697', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110784', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110871', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110958', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111045', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111132', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111306', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111393', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111480', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111567', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111654', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111741', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111915', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112002', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112089', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112176', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112263', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112350', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112437', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112524', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112611', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112698', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112785', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112872', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1112959', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113046', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113133', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113220', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113307', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113394', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113481', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113568', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113655', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113742', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113829', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1113916', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114003', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114090', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114177', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114264', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1114351', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111219', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108435', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107043', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106347', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105999', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105825', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105738', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1111828', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108957', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107478', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106695', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106260', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106086', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105912', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Mantle-Cell', 'efo_term': 'Mantle cell lymphoma', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1081 | Q34 | What are the names of the genes that are targeted by the drug Enzalutamide in the treatment of prostate adenocarcinoma? | In the context of prostate adenocarcinoma, the drug Enzalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate adenocarcinoma%" OR LOWER(efo_term) LIKE "%prostate adenocarcinoma%") AND (LOWER(drugName) LIKE "%enzalutamide%" OR LOWER(tradeNames_list) LIKE "%enzalutamide%" OR LOWER(syns_list) LIKE "%enzalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921126', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921183', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921202', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921221', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921259', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921278', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921297', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921335', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921354', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921316', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921164', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921050', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921031', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921088', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921240', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921145', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921107', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921069', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1289 | Q34 | What are the names of the genes that are targeted by the drug Selpercatinib in the treatment of medullary thyroid gland carcinoma? | In the context of medullary thyroid gland carcinoma, the drug Selpercatinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%medullary thyroid gland carcinoma%" OR LOWER(efo_term) LIKE "%medullary thyroid gland carcinoma%") AND (LOWER(drugName) LIKE "%selpercatinib%" OR LOWER(tradeNames_list) LIKE "%selpercatinib%" OR LOWER(syns_list) LIKE "%selpercatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944412', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944433', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944440', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944447', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944461', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944468', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944475', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944489', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944496', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944503', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944510', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944524', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944531', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944538', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944545', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944552', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944559', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944566', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944573', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944580', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944587', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944601', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944608', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944615', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944622', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944629', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944643', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944650', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944657', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944664', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944671', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944678', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944685', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944692', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944699', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944706', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944713', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944720', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944727', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944734', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944741', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944748', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944755', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944762', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944769', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944776', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944783', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944790', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944797', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944804', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944811', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944825', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944832', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944839', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944846', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944853', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944860', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944874', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944881', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944888', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944895', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944902', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944909', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944916', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944923', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944930', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944937', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944944', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944951', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944958', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944965', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944972', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944979', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944986', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944993', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945000', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945007', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945014', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945021', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945028', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945035', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945042', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945049', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945056', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945063', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945070', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944818', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944594', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944482', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944426', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944398', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944384', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944377', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944867', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944636', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944517', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944454', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944419', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944405', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944391', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Medullary', 'efo_term': 'medullary thyroid gland carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.61 | Q34 | What are the names of the genes that are targeted by the drug Metoclopramide Hydrochloride in the treatment of Vomiting? | In the context of Vomiting, the drug Metoclopramide Hydrochloride targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 3A and 5-hydroxytryptamine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%vomiting%" OR LOWER(efo_term) LIKE "%vomiting%") AND (LOWER(drugName) LIKE "%metoclopramide hydrochloride%" OR LOWER(tradeNames_list) LIKE "%metoclopramide hydrochloride%" OR LOWER(syns_list) LIKE "%metoclopramide hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199671', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199679', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199683', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199684', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199691', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199692', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199695', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199700', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199703', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199699', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_199676', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199660', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199659', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199667', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199687', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199675', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Vomiting', 'efo_term': 'Vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_199668', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199663', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'"clopra-""yellow"""\', \'Clopra\', \'Clopra-"Yellow"\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'syns_list': "['AHR-3070-C', 'Metipamid', 'Metoclopramide dihydrochloride monohydrateMetoclopramide hcl monohydrate', 'Metoclopramide hydrochlorideMetoclopramide hydrochloride monohydrateMetoclopramide monohydrochloride monohydrateMetoclopramidi hydrochloridum', 'NSC-757117']", 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1345 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of sprain? | In the context of sprain, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sprain%" OR LOWER(efo_term) LIKE "%sprain%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993229', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993155', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993081', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993044', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993266', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993192', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993118', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.94 | Q34 | What are the names of the genes that are targeted by the drug Palonosetron Hydrochloride in the treatment of cancer? | In the context of cancer, the drug Palonosetron Hydrochloride targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%palonosetron hydrochloride%" OR LOWER(tradeNames_list) LIKE "%palonosetron hydrochloride%" OR LOWER(syns_list) LIKE "%palonosetron hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205522', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205540', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205546', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205552', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205564', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205570', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205576', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205588', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205594', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205600', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205606', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205618', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205624', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205630', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205636', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205642', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205648', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205654', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205660', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205666', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205672', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205684', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205690', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205696', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205702', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205708', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205720', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205726', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205732', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205738', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205678', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205582', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205534', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205510', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205498', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205492', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205714', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205612', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205558', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205528', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205516', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205504', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_list': "['Aloxi', 'Palonosetron hydrochloride']", 'syns_list': "['Palonocetron hydrochloride', 'Palonosetron (as hydrochloride)Palonosetron hcl', 'Palonosetron hydrochloride', 'RS-25259-197']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.671 | Q34 | What are the names of the genes that are targeted by the drug Apremilast in the treatment of immune system disease? | In the context of immune system disease, the drug Apremilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%apremilast%" OR LOWER(tradeNames_list) LIKE "%apremilast%" OR LOWER(syns_list) LIKE "%apremilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_696932', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697016', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697044', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697072', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697128', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697156', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697184', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697240', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697268', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697296', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697324', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697380', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697408', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697436', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697464', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697492', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697520', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697548', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697576', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697604', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697632', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697688', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697716', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697744', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697772', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697800', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697856', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697884', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697912', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697940', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697968', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697996', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698024', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698052', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698080', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698108', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698136', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698164', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698192', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698220', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698248', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698276', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698304', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698332', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698360', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698388', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698416', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698444', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698472', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698500', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698528', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698584', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698612', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698640', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698668', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698696', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698724', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698780', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698808', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698836', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698864', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698892', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698920', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698948', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698976', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699004', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699032', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699060', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699088', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699116', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699144', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699172', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699200', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699228', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699256', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699284', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_699312', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699340', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699368', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699396', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699424', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699452', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699480', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699508', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699536', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_699564', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_698556', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697660', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697212', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696988', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696876', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696820', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696792', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_698752', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697828', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697352', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_697100', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696960', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696904', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696848', 'drugName': 'Apremilast', 'tradeNames_list': "['Otezla']", 'syns_list': "['Apremilast', 'CC-10004', 'CC10004']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.282 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Iridocyclitis? | In the context of Iridocyclitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%iridocyclitis%" OR LOWER(efo_term) LIKE "%iridocyclitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227737', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228592', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228877', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229162', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229732', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230017', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230302', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230872', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231157', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231442', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231727', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232297', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230587', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228307', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227167', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226597', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226312', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232012', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229447', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228022', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227452', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226882', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Iridocyclitis', 'efo_term': 'Iridocyclitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1102 | Q34 | What are the names of the genes that are targeted by the drug Darolutamide in the treatment of metastatic prostate cancer? | In the context of metastatic prostate cancer, the drug Darolutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%metastatic prostate cancer%" OR LOWER(efo_term) LIKE "%metastatic prostate cancer%") AND (LOWER(drugName) LIKE "%darolutamide%" OR LOWER(tradeNames_list) LIKE "%darolutamide%" OR LOWER(syns_list) LIKE "%darolutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924421', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924435', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924407', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924393', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924386', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924428', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924414', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924400', 'drugName': 'Darolutamide', 'tradeNames_list': "['Nubeqa']", 'syns_list': "['BAY 1841788', 'BAY-1841788', 'BAY1841788', 'Darolutamide', 'ODM-201Odm-201']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.361 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of skin disease? | In the context of skin disease, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin disease%" OR LOWER(efo_term) LIKE "%skin disease%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232531', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232612', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232639', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232666', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232720', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232747', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232774', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232828', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232855', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232882', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232909', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232963', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232990', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233017', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233044', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233071', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233098', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233125', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233152', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233179', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233206', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233260', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233287', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233314', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233341', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233368', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233422', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233449', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233476', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233503', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233530', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233557', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233584', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233611', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233638', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233665', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233692', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233719', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233746', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233773', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233800', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233827', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233854', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233881', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233908', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233935', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233962', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233989', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234016', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234043', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234070', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234124', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234151', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234178', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234205', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234232', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234259', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234313', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234340', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234367', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234394', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234421', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234448', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234475', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234502', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234529', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234556', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234583', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234610', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234637', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234664', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234691', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234718', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234745', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234772', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234799', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234826', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234853', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234880', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234907', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234934', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234961', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234988', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235015', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235042', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235069', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234097', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233233', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232801', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232585', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232477', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232423', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232396', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234286', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233395', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232936', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232693', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232558', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232504', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232450', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1436 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of Prinzmetal's angina? | In the context of Prinzmetal's angina, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prinzmetal's angina%" OR LOWER(efo_term) LIKE "%prinzmetal's angina%") AND (LOWER(drugName) LIKE "%amlodipine besylate%" OR LOWER(tradeNames_list) LIKE "%amlodipine besylate%" OR LOWER(syns_list) LIKE "%amlodipine besylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1043741', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043783', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043797', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043811', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043839', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043853', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043867', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043895', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043909', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043923', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043937', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043965', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043979', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043993', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043881', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043769', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043713', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043685', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043671', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043951', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043825', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043755', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043727', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043699', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'syns_list': "['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris, Variant', 'efo_term': "Prinzmetal's angina", 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1272 | Q34 | What are the names of the genes that are targeted by the drug Megestrol Acetate in the treatment of inborn errors of immunity? | In the context of inborn errors of immunity, the drug Megestrol Acetate targets the gene progesterone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%inborn errors of immunity%" OR LOWER(efo_term) LIKE "%inborn errors of immunity%") AND (LOWER(drugName) LIKE "%megestrol acetate%" OR LOWER(tradeNames_list) LIKE "%megestrol acetate%" OR LOWER(syns_list) LIKE "%megestrol acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940579', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940516', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940537', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940600', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940558', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Immunodeficiency Diseases', 'efo_term': 'inborn errors of immunity', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.853 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of migraine disorder? | In the context of migraine disorder, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833506', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833062', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832951', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833284', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833395', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833173', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1362 | Q34 | What are the names of the genes that are targeted by the drug Ibrutinib in the treatment of cancer? | In the context of cancer, the drug Ibrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%ibrutinib%" OR LOWER(tradeNames_list) LIKE "%ibrutinib%" OR LOWER(syns_list) LIKE "%ibrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_998391', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995999', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997471', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995033', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996367', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999081', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995539', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995953', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996873', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997057', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997563', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997839', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996229', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998713', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998621', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998805', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998851', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999265', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999127', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996459', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995125', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995447', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996689', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995631', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997011', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996919', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997195', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997793', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995171', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997609', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996137', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997931', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995815', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998023', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998069', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998989', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998437', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998667', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995217', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998943', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998759', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998897', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995493', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999449', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999035', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999219', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999173', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999403', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995263', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999357', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999311', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995585', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996551', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995907', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996781', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996643', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996735', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997379', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996045', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996965', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995677', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997333', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997103', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997287', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997241', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998253', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995355', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997517', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996091', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997747', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995769', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997701', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997655', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998207', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996183', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997885', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995401', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998161', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997977', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998115', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995861', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999495', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998345', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998529', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998483', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999587', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_999541', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998299', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997425', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996827', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996597', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996505', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996275', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995309', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_997149', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995079', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_998575', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996413', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_995723', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_996321', 'drugName': 'Ibrutinib', 'tradeNames_list': "['Imbruvica']", 'syns_list': "['CRA-032765', 'Ibrutinib', 'PC-32765', 'PCI 32765', 'PCI-32765PCI-32765-00']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.112 | Q34 | What are the names of the genes that are targeted by the drug Duloxetine Hydrochloride in the treatment of fibromyalgia? | In the context of fibromyalgia, the drug Duloxetine Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fibromyalgia%" OR LOWER(efo_term) LIKE "%fibromyalgia%") AND (LOWER(drugName) LIKE "%duloxetine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%duloxetine hydrochloride%" OR LOWER(syns_list) LIKE "%duloxetine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206077', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206125', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206141', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206157', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206189', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206205', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206221', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206253', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206269', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206285', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206301', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206333', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206349', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206365', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206381', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206397', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206413', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206429', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206445', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206461', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206477', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206493', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206237', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206109', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206045', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206013', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_205997', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206317', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206173', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206093', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206061', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206029', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'syns_list': "['Ariclaim', 'Duloxetine (as hydrochloride)', 'Duloxetine hclDuloxetine hydrochloride', 'Duloxetine mylan', 'LY-248686', 'LY-248686 HCLLY248686 HCL', 'NSC-759112', 'Xeristar']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.43 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of schizoaffective disorder? | In the context of schizoaffective disorder, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizoaffective disorder%" OR LOWER(efo_term) LIKE "%schizoaffective disorder%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_160883', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159483', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159987', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160351', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161135', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161415', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161555', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159259', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159539', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159679', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160099', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160407', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160547', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161107', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161023', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161191', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161219', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161527', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161443', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161611', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161639', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159147', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159315', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159343', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159651', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159567', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159763', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160323', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160015', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160183', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160211', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160519', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160435', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160603', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160631', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161331', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160911', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161079', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161051', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161303', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161163', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161275', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161247', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161751', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161387', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161499', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161471', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161723', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161583', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161695', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161667', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159091', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159203', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159175', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159427', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159287', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159399', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159875', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159511', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159623', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159595', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159847', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159707', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159819', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159791', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160771', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159959', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160071', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160043', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160295', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160155', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160267', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160239', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160743', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160379', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160491', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160463', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160715', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160575', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160687', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160659', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161779', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160855', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160967', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160939', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161835', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161807', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160799', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159903', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159455', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159231', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159119', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159063', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159371', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159735', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160127', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160995', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_161359', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_159931', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_160827', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'syns_list': "['Abilify mycite', 'Aripiprazole', 'Aripiprex', 'NSC-759266', 'OPC-14597OPC-31']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.127 | Q34 | What are the names of the genes that are targeted by the drug Levomilnacipran Hydrochloride in the treatment of fibromyalgia? | In the context of fibromyalgia, the drug Levomilnacipran Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fibromyalgia%" OR LOWER(efo_term) LIKE "%fibromyalgia%") AND (LOWER(drugName) LIKE "%levomilnacipran hydrochloride%" OR LOWER(tradeNames_list) LIKE "%levomilnacipran hydrochloride%" OR LOWER(syns_list) LIKE "%levomilnacipran hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206893', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206905', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206909', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206913', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206921', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206925', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206929', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206937', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206941', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206945', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206949', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206957', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206961', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206965', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206933', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206901', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206885', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206877', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206873', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206953', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206917', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206897', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206889', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206881', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibromyalgia', 'efo_term': 'fibromyalgia', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.206 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of subacute thyroiditis? | In the context of subacute thyroiditis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%subacute thyroiditis%" OR LOWER(efo_term) LIKE "%subacute thyroiditis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218712', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219336', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219544', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219752', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220168', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220376', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220584', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220792', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219128', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218296', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217880', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217672', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219960', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218920', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218504', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218088', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroiditis, Subacute', 'efo_term': 'subacute thyroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.53 | Q34 | What are the names of the genes that are targeted by the drug Asenapine in the treatment of psychosis? | In the context of psychosis, the drug Asenapine targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psychosis%" OR LOWER(efo_term) LIKE "%psychosis%") AND (LOWER(drugName) LIKE "%asenapine%" OR LOWER(tradeNames_list) LIKE "%asenapine%" OR LOWER(syns_list) LIKE "%asenapine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197844', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197874', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197868', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197826', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197811', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197814', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197838', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197895', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197886', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197808', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197889', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197832', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197871', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197820', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197829', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197847', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197880', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197877', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197856', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197883', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197859', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197892', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197823', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197865', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197850', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197862', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197853', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197835', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197817', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197841', 'drugName': 'Asenapine', 'tradeNames_list': "['Secuado', 'Sycrest']", 'syns_list': "['Asenapine']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197605', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197659', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197767', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197665', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197779', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197785', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197611', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197671', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197791', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197797', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197677', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197803', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197617', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197683', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197689', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197569', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197587', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197623', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197695', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197701', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197629', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197581', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197773', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197707', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197713', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197557', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197593', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197635', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197761', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197575', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197647', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197719', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197599', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197563', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197743', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197749', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197653', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197755', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197725', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197641', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197731', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_197737', 'drugName': 'Asenapine Maleate', 'tradeNames_list': "['Saphris']", 'syns_list': "['Asenapine (as maleate)', 'Asenapine maleate', 'ORG 5222', 'ORG-5222']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'psychosis', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.549 | Q34 | What are the names of the genes that are targeted by the drug Levocetirizine Dihydrochloride in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Levocetirizine Dihydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%levocetirizine dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%levocetirizine dihydrochloride%" OR LOWER(syns_list) LIKE "%levocetirizine dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455993', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'syns_list': "['Cetirizine (r)-form dihydrochloride', 'Cetirizine hydrochloride (r)-Levocetirizine dihydrochloride', 'Levocetirizine hydrochlorideLevocetirizine monohydrochloride', 'NSC-758898', 'UCB 28556', 'UCB-28556']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.69 | Q34 | What are the names of the genes that are targeted by the drug Pramipexole Dihydrochloride in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Pramipexole Dihydrochloride targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%pramipexole dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%pramipexole dihydrochloride%" OR LOWER(syns_list) LIKE "%pramipexole dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199729', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199741', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199745', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199749', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199757', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199761', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199765', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199773', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199777', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199781', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199785', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199793', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199797', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199801', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199805', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199809', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199813', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199817', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199821', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199825', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199829', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199837', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199841', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199845', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199849', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199853', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199861', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199865', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199869', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199873', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199833', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199769', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199737', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199721', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199713', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199709', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199857', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_199789', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199753', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199733', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199725', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199717', 'drugName': 'Pramipexole Dihydrochloride', 'tradeNames_list': "['Mirapex', 'Mirapex Extended Release', 'Mirapex erPramipexole dihydrochloride']", 'syns_list': "['Daquiran', 'PNU-98528E', 'Pramipexole accordPramipexole dihydrochloride', 'Pramipexole dihydrochloride anhydrousPramipexole dihydrochloride monohydrate', 'Pramipexole hydrochloridePramipexole hydrochloride hydrate', 'Pramipexole teva', 'SND-919CL2YSND919CL2Y', 'Sifrol']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1124 | Q34 | What are the names of the genes that are targeted by the drug Binimetinib in the treatment of neoplasm? | In the context of neoplasm, the drug Binimetinib targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%binimetinib%" OR LOWER(tradeNames_list) LIKE "%binimetinib%" OR LOWER(syns_list) LIKE "%binimetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_926835', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927095', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926965', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926755', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927069', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926939', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926781', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926989', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927041', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927119', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926783', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927121', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927093', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926809', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926653', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926833', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926991', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926731', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926887', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926807', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926885', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926861', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927147', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926757', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926859', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927145', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926963', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927017', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926705', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926679', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927015', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926729', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927067', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926937', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926913', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927043', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926677', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926911', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926703', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926651', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927039', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927040', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926804', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927142', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926674', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926806', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927092', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927144', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926650', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927091', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926675', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926884', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927116', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926832', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926987', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926752', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927090', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926727', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926676', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927014', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926726', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926908', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926728', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926910', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927064', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926883', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927143', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926934', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926831', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926986', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927065', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926935', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926936', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926882', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926700', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926961', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927012', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926960', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926701', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926830', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926962', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927066', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926648', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926702', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926805', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926909', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926754', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926858', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926753', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926778', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926779', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926780', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926856', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926857', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_926988', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_926649', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927013', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927038', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927117', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927118', 'drugName': 'Binimetinib', 'tradeNames_list': "['Mektovi']", 'syns_list': "['ARRY 438162', 'ARRY-162', 'ARRY-438162', 'Binimetinib', 'MEK-162', 'MEK162Mek-162', 'NVP-MEK162']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1731 | Q34 | What are the names of the genes that are targeted by the drug Inotersen Sodium in the treatment of familial amyloid neuropathy? | In the context of familial amyloid neuropathy, the drug Inotersen Sodium targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%familial amyloid neuropathy%" OR LOWER(efo_term) LIKE "%familial amyloid neuropathy%") AND (LOWER(drugName) LIKE "%inotersen sodium%" OR LOWER(tradeNames_list) LIKE "%inotersen sodium%" OR LOWER(syns_list) LIKE "%inotersen sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097657', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097645', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097642', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097651', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097654', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097648', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'syns_list': "['Inotersen sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloid Neuropathies, Familial', 'efo_term': 'familial amyloid neuropathy', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.185 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218691', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219315', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219523', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219731', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220147', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220355', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220563', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220771', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219107', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218275', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217859', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217651', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219939', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218899', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218483', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218067', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.139 | Q34 | What are the names of the genes that are targeted by the drug Osimertinib Mesylate in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Osimertinib Mesylate targets the gene epidermal growth factor receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%osimertinib mesylate%" OR LOWER(tradeNames_list) LIKE "%osimertinib mesylate%" OR LOWER(syns_list) LIKE "%osimertinib mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217149', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217155', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217157', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217159', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217163', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217165', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217167', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217171', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217173', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217169', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217153', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217141', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217139', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217145', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217161', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217151', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217147', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217143', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.905 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of Myalgia? | In the context of Myalgia, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myalgia%" OR LOWER(efo_term) LIKE "%myalgia%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838533', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838656', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838697', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838738', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838820', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838861', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838902', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838984', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839025', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839066', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839107', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839189', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839230', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839271', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839312', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839353', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839394', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839435', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839476', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839517', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839558', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839640', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839681', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839599', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838943', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838615', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838369', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838328', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838451', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839148', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838779', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838574', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838492', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838410', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.802 | Q34 | What are the names of the genes that are targeted by the drug Estradiol Acetate in the treatment of menopause? | In the context of menopause, the drug Estradiol Acetate targets the gene estrogen receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%menopause%" OR LOWER(efo_term) LIKE "%menopause%") AND (LOWER(drugName) LIKE "%estradiol acetate%" OR LOWER(tradeNames_list) LIKE "%estradiol acetate%" OR LOWER(syns_list) LIKE "%estradiol acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823877', 'drugName': 'Estradiol Acetate', 'tradeNames_list': "['Femring', 'Femtrace']", 'syns_list': "['E3A', 'ESTRADIOL-3-ACETATE', 'Estradiol 3-acetate', 'Estradiol acetate']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823879', 'drugName': 'Estradiol Acetate', 'tradeNames_list': "['Femring', 'Femtrace']", 'syns_list': "['E3A', 'ESTRADIOL-3-ACETATE', 'Estradiol 3-acetate', 'Estradiol acetate']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_823881', 'drugName': 'Estradiol Acetate', 'tradeNames_list': "['Femring', 'Femtrace']", 'syns_list': "['E3A', 'ESTRADIOL-3-ACETATE', 'Estradiol 3-acetate', 'Estradiol acetate']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.134 | Q34 | What are the names of the genes that are targeted by the drug Afatinib in the treatment of cancer? | In the context of cancer, the drug Afatinib targets the gene epidermal growth factor receptor, erb-b2 receptor tyrosine kinase 2 and erb-b2 receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%afatinib%" OR LOWER(tradeNames_list) LIKE "%afatinib%" OR LOWER(syns_list) LIKE "%afatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_207795', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208575', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209589', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207925', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207691', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209433', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207743', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208159', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208055', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207847', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208991', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208393', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207951', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209511', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208419', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209537', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209485', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207821', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208549', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208601', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207665', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207457', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208211', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208133', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208783', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207379', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208263', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209121', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207483', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209017', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208341', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209225', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209147', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209043', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209251', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209329', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207509', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208653', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208523', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209615', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207977', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208107', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208471', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207873', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207535', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208497', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209693', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209303', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208185', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209277', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209641', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207561', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208029', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207431', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208731', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207405', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208705', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208939', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207587', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208289', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208237', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208913', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208809', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208887', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208861', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209381', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207613', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208445', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208367', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_209095', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208081', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209069', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209563', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209355', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_207639', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209199', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209173', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209407', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208965', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208757', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208315', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208003', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207769', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_209459', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_209667', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_208679', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208835', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207899', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208627', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207717', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207716', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208184', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207404', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208574', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_208626', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207742', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207456', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207560', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_208600', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_207768', 'drugName': 'Afatinib', 'tradeNames_list': "['Gilotrif', 'Giotrif']", 'syns_list': "['Afatinib', 'BIBW-2992', 'BIBW2992', 'Bibw 2992', 'NSC-750691', 'TomtovokTovok']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.82 | Q34 | What are the names of the genes that are targeted by the drug Bromocriptine Mesylate in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Bromocriptine Mesylate targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%bromocriptine mesylate%" OR LOWER(tradeNames_list) LIKE "%bromocriptine mesylate%" OR LOWER(syns_list) LIKE "%bromocriptine mesylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201378', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201399', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201406', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201413', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201427', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201434', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201441', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201455', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201462', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201469', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201476', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201490', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201497', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201504', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201511', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201518', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201525', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201532', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201539', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201546', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201553', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201567', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201574', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201581', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201588', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201595', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201609', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201616', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201623', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201630', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201637', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201644', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201651', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201658', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201665', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201672', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201679', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201686', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201693', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201700', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201707', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201714', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201721', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201728', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201735', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201742', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201749', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201756', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201763', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201770', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201777', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201791', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201798', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201805', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201812', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201819', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201826', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201840', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201847', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201854', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201861', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201868', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201875', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201882', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201889', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201896', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201903', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201910', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201917', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201924', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201931', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201938', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201945', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201952', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201959', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201966', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201973', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201980', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201987', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201994', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202001', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202008', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202015', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202022', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202029', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_202036', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201784', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201560', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201448', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201392', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201364', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201350', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201343', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201833', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201602', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201483', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201420', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201385', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201371', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201357', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'syns_list': "['2-bromoergocryptine mesylate', 'Bromocriptine mesilateBromocriptine mesylate', 'Bromocriptine methanesulfonate', 'CB-154CB-154 MESYLATE', 'Cb-154 mesilate', 'NSC-755915']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1836 | Q34 | What are the names of the genes that are targeted by the drug Plerixafor in the treatment of multiple myeloma? | In the context of multiple myeloma, the drug Plerixafor targets the gene C-X-C motif chemokine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple myeloma%" OR LOWER(efo_term) LIKE "%multiple myeloma%") AND (LOWER(drugName) LIKE "%plerixafor%" OR LOWER(tradeNames_list) LIKE "%plerixafor%" OR LOWER(syns_list) LIKE "%plerixafor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103211', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1103248', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.545 | Q34 | What are the names of the genes that are targeted by the drug Olopatadine Hydrochloride in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Olopatadine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%olopatadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%olopatadine hydrochloride%" OR LOWER(syns_list) LIKE "%olopatadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455973', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455957', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455953', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455965', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455969', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455961', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1581 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of Kidney Angiomyolipoma? | In the context of Kidney Angiomyolipoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%kidney angiomyolipoma%" OR LOWER(efo_term) LIKE "%kidney angiomyolipoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085639', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086044', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086179', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086314', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086584', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086719', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086854', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087124', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087259', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087394', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087529', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087799', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087934', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088069', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088204', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088339', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088474', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088609', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088744', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088879', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089014', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089284', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089419', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089554', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089689', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089824', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090094', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090229', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090364', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090499', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090634', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089149', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086989', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085909', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085369', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085099', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084964', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089959', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087664', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086449', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085774', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085504', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085234', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.990 | Q34 | What are the names of the genes that are targeted by the drug Palbociclib in the treatment of breast cancer? | In the context of breast cancer, the drug Palbociclib targets the gene cyclin dependent kinase 4, cyclin dependent kinase 6 and cyclin D1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%palbociclib%" OR LOWER(tradeNames_list) LIKE "%palbociclib%" OR LOWER(syns_list) LIKE "%palbociclib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_851579', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851711', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851755', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851799', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851887', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851931', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851975', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852063', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852107', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852151', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852195', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852283', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852327', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852371', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852415', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852459', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852503', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852547', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852591', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852635', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852679', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852767', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852811', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852855', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852899', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852943', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853031', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853075', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853119', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853163', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853207', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853251', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853295', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853339', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853383', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853427', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853471', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853515', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853559', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853603', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853647', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853691', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853735', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853779', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853823', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853867', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853911', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853955', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_853999', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_854043', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_854087', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_854175', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_854219', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_854263', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854307', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854351', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854395', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854483', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854527', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854571', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854615', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854659', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854703', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854747', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854791', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854835', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854879', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854923', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854967', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855011', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855055', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855099', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855143', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855187', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855231', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855275', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855319', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855363', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855407', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855451', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855495', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855539', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855583', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855627', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855671', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_855715', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_854131', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852723', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_852019', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851667', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851491', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851403', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851359', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_854439', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CCND1', 'approvedName': 'cyclin D1'}, {'UUID': 'DrugTargetsIndication121923_text_852987', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_852239', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851843', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851623', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851535', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851447', 'drugName': 'Palbociclib', 'tradeNames_list': "['Ibrance']", 'syns_list': "['PD-0332991', 'Palbociclib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.167 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of psoriasis? | In the context of psoriasis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218673', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219297', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219505', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219713', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220129', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220337', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220545', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220753', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219089', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218257', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217841', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217633', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219921', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218881', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218465', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218049', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.250 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of lateral epicondylitis? | In the context of lateral epicondylitis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lateral epicondylitis%" OR LOWER(efo_term) LIKE "%lateral epicondylitis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222210', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222340', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222080', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221950', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221885', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222275', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222145', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222015', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tennis Elbow', 'efo_term': 'lateral epicondylitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.450 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of cardiac arrest? | In the context of cardiac arrest, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiac arrest%" OR LOWER(efo_term) LIKE "%cardiac arrest%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_363105', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362051', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362204', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360985', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360885', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361780', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361839', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361091', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362634', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360938', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362793', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361568', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361197', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363164', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360991', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361250', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361733', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363270', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360832', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363317', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361044', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361945', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361992', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360826', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362681', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361097', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362157', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362893', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360879', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362840', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361150', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362946', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362369', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362416', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361621', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363264', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361203', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363158', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361680', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363217', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361727', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363211', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361256', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363370', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361786', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361303', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361833', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363323', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361309', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361886', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361892', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361939', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361674', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361362', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362581', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361998', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361409', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362740', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361415', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362098', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362104', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362734', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362151', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362687', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361468', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363052', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362210', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361515', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362257', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362846', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361521', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362310', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362316', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363005', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362363', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362899', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361574', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362999', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362422', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362952', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362469', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363376', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361627', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362522', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362528', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363429', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363423', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363058', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362787', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362628', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362575', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361356', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360932', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362045', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361462', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362263', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363111', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361038', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361144', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'sudden cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362475', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Arrest', 'efo_term': 'cardiac arrest', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1136 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of pancreatic ductal adenocarcinoma? | Trametinib has not been approved by the FDA as a treatment for pancreatic ductal adenocarcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pancreatic ductal adenocarcinoma%" OR LOWER(efo_term) LIKE "%pancreatic ductal adenocarcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928684', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928804', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928844', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928884', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928964', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929004', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929044', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929124', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929164', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929204', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929244', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929324', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929364', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929404', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929444', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929484', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929524', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929564', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929604', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929644', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929684', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929764', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929804', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929844', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929884', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929924', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930004', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930044', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930084', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930124', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930164', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930204', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930244', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930284', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930324', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930364', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930404', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930444', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930484', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930524', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930564', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930604', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930644', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930684', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930724', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930764', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930804', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930844', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930884', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930924', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930964', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931044', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931084', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931124', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931164', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931204', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931244', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931324', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931364', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931404', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931444', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931484', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931524', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931564', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931604', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931644', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931684', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931724', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931764', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931804', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931844', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931884', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931924', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931964', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932004', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932044', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932084', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932124', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932164', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932204', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932244', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932284', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932324', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932364', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932404', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932444', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931004', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929724', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929084', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928764', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928604', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928524', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928484', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931284', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929964', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929284', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928924', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928724', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928644', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928564', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Carcinoma, Pancreatic Ductal', 'efo_term': 'pancreatic ductal adenocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.864 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of pain? | In the context of pain, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_835527', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835376', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834585', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834114', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835841', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834120', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835370', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833643', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835998', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833963', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834591', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833800', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835056', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834428', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834905', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834271', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833806', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835062', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835684', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834742', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834277', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835219', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835533', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835847', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836004', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835213', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835690', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833649', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834899', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833957', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834434', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834748', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833562', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834347', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835289', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834504', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834033', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835603', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835760', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835446', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833719', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834661', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835917', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_833876', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834190', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834818', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834975', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835132', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1199 | Q34 | What are the names of the genes that are targeted by the drug Capmatinib Hydrochloride in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Capmatinib Hydrochloride targets the gene MET proto-oncogene, receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%capmatinib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%capmatinib hydrochloride%" OR LOWER(syns_list) LIKE "%capmatinib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_936122', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936125', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936126', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936124', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936118', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936117', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936120', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936123', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936121', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_936119', 'drugName': 'Capmatinib Hydrochloride', 'tradeNames_list': "['Tabrecta']", 'syns_list': "['Capmatinib hydrochloride', 'Capmatinib hydrochloride hydrateNVP-INC280-AAA']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.99 | Q34 | What are the names of the genes that are targeted by the drug Granisetron in the treatment of cancer? | In the context of cancer, the drug Granisetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%granisetron%" OR LOWER(tradeNames_list) LIKE "%granisetron%" OR LOWER(syns_list) LIKE "%granisetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205820', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205764', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205750', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205792', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205806', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205778', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1954 | Q34 | What are the names of the genes that are targeted by the drug Baclofen in the treatment of cerebral palsy? | In the context of cerebral palsy, the drug Baclofen targets the gene gamma-aminobutyric acid type B receptor subunit 1 and gamma-aminobutyric acid type B receptor subunit 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cerebral palsy%" OR LOWER(efo_term) LIKE "%cerebral palsy%") AND (LOWER(drugName) LIKE "%baclofen%" OR LOWER(tradeNames_list) LIKE "%baclofen%" OR LOWER(syns_list) LIKE "%baclofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193246', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193321', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193346', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193296', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193146', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193121', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193196', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193271', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193221', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193171', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cerebral Palsy', 'efo_term': 'cerebral palsy', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.742 | Q34 | What are the names of the genes that are targeted by the drug Morphine Sulfate in the treatment of drug dependence? | In the context of drug dependence, the drug Morphine Sulfate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%drug dependence%" OR LOWER(efo_term) LIKE "%drug dependence%") AND (LOWER(drugName) LIKE "%morphine sulfate%" OR LOWER(tradeNames_list) LIKE "%morphine sulfate%" OR LOWER(syns_list) LIKE "%morphine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763499', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763556', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763575', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763594', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763632', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763651', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763670', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763708', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763727', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763746', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763765', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763803', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763822', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763841', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763860', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763879', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763898', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763917', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763936', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763955', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763974', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764012', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_764031', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763993', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763689', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763537', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763423', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763404', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763461', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763784', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763613', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763518', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763480', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763442', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'drug dependence', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1240 | Q34 | What are the names of the genes that are targeted by the drug Vibegron in the treatment of urgency urinary incontinence? | In the context of urgency urinary incontinence, the drug Vibegron targets the gene adrenoceptor beta 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%urgency urinary incontinence%" OR LOWER(efo_term) LIKE "%urgency urinary incontinence%") AND (LOWER(drugName) LIKE "%vibegron%" OR LOWER(tradeNames_list) LIKE "%vibegron%" OR LOWER(syns_list) LIKE "%vibegron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938260', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_938265', 'drugName': 'Vibegron', 'tradeNames_list': "['Gemtesa']", 'syns_list': "['KRP-114V', 'Mk4618', 'Vibegron']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Incontinence, Urge', 'efo_term': 'urgency urinary incontinence', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.104 | Q34 | What are the names of the genes that are targeted by the drug Ondansetron in the treatment of Nausea? | In the context of Nausea, the drug Ondansetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea%" OR LOWER(efo_term) LIKE "%nausea%") AND (LOWER(drugName) LIKE "%ondansetron%" OR LOWER(tradeNames_list) LIKE "%ondansetron%" OR LOWER(syns_list) LIKE "%ondansetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205863', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205900', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205901', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205902', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205937', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205938', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205940', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205942', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205943', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205977', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205978', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205981', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205982', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205983', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205941', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205898', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205861', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205858', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205857', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205980', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205903', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205897', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205862', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205860', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.438 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361084', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361243', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361296', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361349', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361455', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361508', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361561', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361667', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361720', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361773', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361826', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361932', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361985', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362038', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362091', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362144', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362197', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362250', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362303', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362356', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362409', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362515', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362568', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362621', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362674', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362727', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362833', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362886', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362939', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362992', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363045', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363098', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363151', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363204', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363257', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363310', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363363', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363416', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363469', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363522', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363575', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363628', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363681', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363734', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363787', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363840', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363893', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363946', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363999', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364052', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364105', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364211', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364264', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364317', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364370', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364423', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364476', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364582', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364635', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364688', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364741', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364794', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364847', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364900', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364953', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365006', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365059', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365112', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365165', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365218', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365271', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365324', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365377', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365430', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365483', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365536', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365589', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365642', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365695', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365748', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365801', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365854', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365907', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365960', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366013', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366066', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364158', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362462', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361614', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361190', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360978', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360872', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360819', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364529', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362780', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361879', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361402', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361137', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361031', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360925', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.76 | Q34 | What are the names of the genes that are targeted by the drug Rotigotine in the treatment of Parkinson disease? | In the context of Parkinson disease, the drug Rotigotine targets the gene dopamine receptor D2, dopamine receptor D3 and dopamine receptor D4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%parkinson disease%" OR LOWER(efo_term) LIKE "%parkinson disease%") AND (LOWER(drugName) LIKE "%rotigotine%" OR LOWER(tradeNames_list) LIKE "%rotigotine%" OR LOWER(syns_list) LIKE "%rotigotine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_200737', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200752', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200757', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200762', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200772', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200777', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200782', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200792', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200797', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200802', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200807', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200817', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200822', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200827', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200832', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200837', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200842', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200847', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200852', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200857', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200862', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200872', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200877', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200882', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200887', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200892', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200902', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200907', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200912', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200917', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200922', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200927', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200932', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200937', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200942', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200947', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200952', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200957', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200962', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200967', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200972', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200977', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200982', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200987', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200992', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200997', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201002', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201007', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201012', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201017', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201022', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201032', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201037', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201042', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201047', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201052', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201057', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201067', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201072', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201077', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201082', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201087', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201092', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201097', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201102', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201107', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201112', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201117', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201122', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201127', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_201132', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201137', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201142', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201147', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201152', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201157', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201162', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201167', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201172', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201177', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201182', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201187', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201192', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201197', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201202', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201207', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD4', 'approvedName': 'dopamine receptor D4'}, {'UUID': 'DrugTargetsIndication121923_text_201027', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200867', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200787', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200747', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200727', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200717', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200712', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_201062', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200897', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200812', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200767', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200742', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200732', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_200722', 'drugName': 'Rotigotine', 'tradeNames_list': "['Neupro']", 'syns_list': "['Leganto', 'Rotigotine', 'SPM 962', 'SPM-962']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1775 | Q34 | What are the names of the genes that are targeted by the drug Alendronic Acid in the treatment of bone disease? | In the context of bone disease, the drug Alendronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bone disease%" OR LOWER(efo_term) LIKE "%bone disease%") AND (LOWER(drugName) LIKE "%alendronic acid%" OR LOWER(tradeNames_list) LIKE "%alendronic acid%" OR LOWER(syns_list) LIKE "%alendronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099503', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099496', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099489', 'drugName': 'Alendronate Sodium', 'tradeNames_list': "['Alendronate sodium', 'Binosto', 'Fosamax']", 'syns_list': "['Adrovance', 'Alendronate (as sodium)', 'Alendronate sodiumAlendronate sodium hydrate', 'Alendronate sodium trihydrateAlendronic acid monosodium salt trihydrate', 'Fosavance', 'G-704,650G-704650', 'MK-217', 'NSC-722597', 'NSC-758931', 'Sodium alendronateSodium alendronate trihydrate', 'Vantavo']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'metabolic disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099554', 'drugName': 'Alendronic Acid', 'tradeNames_list': "['Binosto', 'Fosamax']", 'syns_list': "['Alendronate', 'Alendronic Acid', 'Alendronic acid', 'Fosamax']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099522', 'drugName': 'Alendronic Acid', 'tradeNames_list': "['Binosto', 'Fosamax']", 'syns_list': "['Alendronate', 'Alendronic Acid', 'Alendronic acid', 'Fosamax']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099538', 'drugName': 'Alendronic Acid', 'tradeNames_list': "['Binosto', 'Fosamax']", 'syns_list': "['Alendronate', 'Alendronic Acid', 'Alendronic acid', 'Fosamax']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099517', 'drugName': 'Alendronic Acid', 'tradeNames_list': "['Binosto', 'Fosamax']", 'syns_list': "['Alendronate', 'Alendronic Acid', 'Alendronic acid', 'Fosamax']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099549', 'drugName': 'Alendronic Acid', 'tradeNames_list': "['Binosto', 'Fosamax']", 'syns_list': "['Alendronate', 'Alendronic Acid', 'Alendronic acid', 'Fosamax']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099533', 'drugName': 'Alendronic Acid', 'tradeNames_list': "['Binosto', 'Fosamax']", 'syns_list': "['Alendronate', 'Alendronic Acid', 'Alendronic acid', 'Fosamax']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.